Phenyl urea derivatives as N-formyl peptide receptor modulators

Abstract

The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor. ##STR00001##

Claims

1. A compound of Formula I: ##STR00142## wherein: W is —COOH, —C(O)OR.sup.a, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid, boronic acid or Het.sup.1; wherein R.sup.a is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, halogen, —OC.sub.1-8 alkyl and —(OC.sub.1-8 alkylene).sub.q-OC.sub.1-8 alkyl, wherein q is 1, 2, 3, 4, 5 or 6; and wherein Het.sup.1 is a 5-membered heteroaryl optionally substituted with one or more halogen, unsubstituted C.sub.1-6 alkyl, —C.sub.1-6 haloalkyl, —OC.sub.1-6alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl) or —(CH.sub.2).sub.1-6NR.sup.14R.sup.15; R.sup.1 is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-6 alkyl), —NR.sup.16R.sup.17, guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-6 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, and optionally substituted heterocycle; R.sup.2a is H, and R.sup.2 is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-6 alkyl), —NR.sup.16R.sup.17, urea (—NHC(═O)NH.sub.2), guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-6 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, and optionally substituted heterocycle; or R.sup.2 and R.sup.2a form an optionally substituted C.sub.3-8 cycloalkyl or an optionally substituted C.sub.3-8 cycloalkenyl; R.sup.3 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.4 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.11; R.sup.5 is optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —S(O).sub.mR.sup.10, —SR.sup.13 or —R.sup.13; R.sup.6 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.11; R.sup.7 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.8 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.9 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.10 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.11 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.12 is H or optionally substituted C.sub.1-8 alkyl; R.sup.13 is H, optionally substituted C.sub.1-8 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.14 is C.sub.1-6 alkyl; R.sup.15 is C.sub.1-6 alkyl; R.sup.16 is C.sub.1-6 alkyl; R.sup.17 is C.sub.1-6 alkyl; R.sup.x is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; k is 0, 1 or 2; each m is independently 1 or 2; and either n is 0, p is 1 and R.sup.1 is absent, or n is 1, p is 0 and R.sup.2 is absent; provided that when p is 0, then R.sup.2a is H; or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

2. The compound of claim 1, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole.

3. The compound of claim 1, wherein k is 0 or 1.

4. The compound of claim 1, wherein n is 0, p is 1, k is 0, and R.sup.2a is H, having the following structure: ##STR00143## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

5. The compound of claim 1, wherein n is 0, p is 1, k is 1, and R.sup.2a is H, having the following structure: ##STR00144## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

6. The compound of claim 1, wherein n is 1, p is 0, k is 0, and R.sup.2a is H, having the following structure: ##STR00145## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

7. The compound of claim 1, wherein n is 1, p is 0, k is 1, and R.sup.2a is H, having the following structure: ##STR00146## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

8. The compound of claim 1, wherein n is 0, p is 1, k is 0, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, the compound having the following structure: ##STR00147## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

9. The compound of claim 1, wherein n is 0, p is 1, k is 1, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, the compound having the following structure: ##STR00148## or a mixture of two or more diastereomers thereof; or a mixture of enantiomers thereof; or an individual enantiomer or diastereoisomer thereof; or a pharmaceutically acceptable salt of any one of the foregoing.

10. The compound of claim 1, wherein R.sup.2a is H; k is 0; and either n is 1, p is 0 and R.sup.1 is unsubstituted C.sub.1-6 alkyl, or n is 0, p is 1 and R.sup.2 is unsubstituted C.sub.1-6 alkyl.

11. The compound of claim 1, wherein R.sup.1 or R.sup.2 is isobutyl.

12. The compound of claim 11, wherein: R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; and R.sup.7 is H or F.

13. The compound of claim 1 selected from the group consisting of: ##STR00149## and mixtures of enantiomers thereof; and individual enantiomers or diastereoisomers thereof; and pharmaceutically acceptable salts thereof.

Description

DETAILED DESCRIPTION OF THE INVENTION

(1) It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise.

(2) The term “alkyl”, as used herein, refers to saturated, monovalent hydrocarbon moieties having linear or branched moieties or combinations thereof. Alkyl groups typically contain 1 to 6 carbon atoms (i.e., C.sub.1-6 alkyl), but may contain a variable number of carbon atoms as specified. For example, an alkyl group may comprise 1 to 4 carbon atoms (i.e., C.sub.1 alkyl), or 1 to 3 carbon atoms (i.e., C.sub.1-3 alkyl). Alkyl groups are optionally substituted with one or more groups including, but not limited to: halogen, hydroxyl, cycloalkyl, heterocycle, aryl, ether, amine, nitro, nitrile, amide, sulfonamide, ester, aldehyde, carboxylic acid, ketone, sulfonic acid, phosphonic acid, and/or phosphoric acid. For example, substituted alkyl includes haloalkyl, such as perhaloalkyl or perfluoroalkyl (e.g., —CF.sub.3). In a further example, substituted alkyl includes C.sub.1 alkyl substituted with C.sub.1-6 aryl (e.g., benzyl, which is —CH.sub.2-phenyl). One or more methylene (CH.sub.2) groups of an alkyl can be replaced by oxygen, sulfur, NH, carbonyl, sulfoxide, sulfonyl, or by a divalent C.sub.3-8 cycloalkyl; one or more methine (CH) groups of an alkyl can be replaced by nitrogen. Unsubstituted C.sub.1-4 alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl. Unsubstituted C.sub.1-3 alkyl includes methyl, ethyl, n-propyl and isopropyl.

(3) The term “alkylene” as used herein refers to a bivalent saturated aliphatic radical derived from an alkene by opening of the double bond, or from an alkane by removal of two hydrogen atoms from different carbon atoms. An alkylene may comprise 1 to 8 carbon atoms (i.e., C.sub.1-8 alkylene), for example, a C.sub.1 alkylene is methylene (—CH.sub.2—); a C.sub.2 alkylene is ethylene (—CH.sub.2CH.sub.2—), and so on.

(4) The term “cycloalkyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms (i.e., C.sub.3-8 cycloalkyl) derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl groups are optionally substituted with one or more groups including, but not limited to: halogen, hydroxyl, alkyl, cycloalkyl, heterocycle, aryl, ether, amine, nitro, nitrile, amide, sulfonamide, ester, aldehyde, carboxylic acid, ketone, sulfonic acid, phosphonic acid, and/or phosphoric acid.

(5) The term “cycloalkenyl”, as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms (i.e., C.sub.3-8 cycloalkenyl) derived from a saturated cycloalkyl having one or more double bonds. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups are optionally substituted by one or more groups including, but not limited to: halogen, hydroxyl, alkyl, cycloalkyl, heterocycle, aryl, ether, amine, nitro, nitrile, amide, sulfonamide, ester, aldehyde, carboxylic acid, ketone, sulfonic acid, phosphonic acid, and/or phosphoric acid.

(6) The term “heterocycle” as used herein, refers to a 3 to 10 membered ring, which can be aromatic (i.e., a heteroaryl) or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected from the group consisting of O, N and S, and combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be interrupted by one or more C═O; the S and/or N heteroatom can be oxidized. Heterocyclic groups can be monocyclic or polycyclic. Heterocyclic ring moieties are optionally substituted with one or more groups including, but not limited to: halogen, hydroxyl, alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl), —(CH.sub.2).sub.1-6N(C.sub.1-6 alkyl).sub.2, haloalkyl, cycloalkyl, heterocycle, aryl, ether, amino, alkylamino, nitro, nitrile, amide, sulfonamide, ester, aldehyde, carboxylic acid, ketone, sulfonic acid, phosphonic acid, and/or phosphoric acid.

(7) The term “aryl” as used herein, refers to an aromatic hydrocarbon ring containing 6 to 10 carbon atoms (i.e., C.sub.6-10 aryl). Aryl groups are optionally substituted by one or more groups including, but not limited to: halogen, hydroxyl, alkyl, cycloalkyl, heterocycle, aryl, ether, amine, nitro, nitrile, amide, sulfonamide, ester, aldehyde, carboxylic acid, ketone, sulfonic acid, phosphonic acid, and/or phosphoric acid. Aryl can be monocyclic or polycyclic.

(8) The term “halogen”, as used herein, refers to an atom of chlorine, bromine, fluorine and/or iodine.

(9) The term “amine” or “amino” as used herein, represents a group of formula “—NR.sup.xR.sup.y”, wherein R.sup.x and R.sup.y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(10) The term “amide” as used herein, represents a group of formula “—C(O)N(R.sup.x)(R.sup.y)” or “—NR.sup.xC(O)R.sup.y” wherein R.sup.x and R.sup.y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(11) The term “sulfonamide” as used herein, represents a group of formula “—S(O).sub.2N(R.sup.x)(R.sup.y)” or “—NR.sup.xS(O).sub.2R.sup.y” wherein R.sup.x and R.sup.y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(12) The term “aldehyde” as used herein, represents a group of formula “—C(O)H”.

(13) The term “ester” as used herein, represents a group of formula “—C(O)O(R.sup.x)”, wherein R.sup.x is alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(14) The term “ketone” as used herein, represents a group of formula “—C(O)R.sup.x” wherein R.sup.x is alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(15) The term “hydroxyl” as used herein, represents a group of formula “—OH”.

(16) The term “carbonyl” as used herein, represents a group of formula “—C(O)—”.

(17) The term “carboxyl” as used herein, represents a group of formula “—C(O)O—”.

(18) The term “carboxylic acid” as used herein, represents a group of formula “—C(O)OH”.

(19) The term “carboxylate” as used herein, represents a group of formula “—C(O)O—”.

(20) The term “sulfoxide” as used herein, represents a group of formula “—S(O)—”.

(21) The term “sulfonyl” as used herein, represents a group of formula “—SO.sub.2—”.

(22) The term “sulfate” as used herein, represents a group of formula “—OS(O).sub.2O—”.

(23) The term “sulphonic acid” as used herein, represents a group of formula “—S(O).sub.2OH”.

(24) The term “phosphonic acid” as used herein, represents a group of formula “—P(O)(OH).sub.2”.

(25) The term “phosphoric acid” as used herein, represents a group of formula “—(O)P(O)(OH).sub.2”.

(26) The term “nitro” as used herein, represents a group of formula “—NO.sub.2”.

(27) The term “nitrile” as used herein, represents a group of formula “—CN”.

(28) The term “ether” as used herein, represents a group of formula “—OR.sup.x”, wherein R is alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(29) The term “thioether” as used herein, represents a group of formula “—SR.sup.x”, wherein R.sup.x is alkyl, aryl, cycloalkyl, cycloalkenyl or heterocycle, as defined above.

(30) The term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

(31) The term “carboxylate isostere”, as used herein, refers to a moiety that replaces a carboxylic acid, such as a moiety selected from the group consisting of sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid, and unsubstituted or substituted 5-membered heteroaryl, preferably tetrazole, imidazole, thiazole, oxazole, triazole, thiophene, pyrazole or pyrole; and wherein said heteroaryl substituent is selected from the group consisting of halogen, —C.sub.1-6 alkyl, —C.sub.1-6 haloalkyl, —OC.sub.1-6alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl) and —(CH.sub.2).sub.1-6N(C.sub.1-6 alkyl).sub.2 wherein each C.sub.1-6 alkyl is the same or different.

(32) The term “therapeutically effective amount” means the amount of a pharmaceutical composition that will elicit a biological or medical response in a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician.

(33) The term “pharmaceutically acceptable salts” refers to salts or complexes that retain the desired biological activity of compounds of the invention, and exhibit minimal or no undesired toxicological effects. The “pharmaceutically acceptable salts” according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I, II or A are able to form. Some compounds of the invention may form salts with acids or bases, including pharmaceutically acceptable acids or bases. Such pharmaceutically acceptable salts of the compounds described herein are within the scope of the invention.

(34) The acid addition salt form of a compound of Formula I, II or A that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric acid, methylsulfonic acid, ethanesulfonic acid, benzenesulfonic acid, formic acid and the like. The base addition salt form of a compound of Formula I, II or A that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like, or an organic base such as for example, L-arginine, ethanolamine, betaine, benzathine, morpholine and the like. (See Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta, Zürich, 2002, 329-345.)

(35) The compounds of Formula I, II or A and some of their intermediates have at least one asymmetric center in their structure. This assymetric center (or chiral center) may be present in an R or S configuration, said R or S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-13. As such, the compounds of Formula I, II or A may exist in enantiomeric as well as diastereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula I, II or A, as well as mixtures thereof, including racemic mixtures, form part of the present invention. Graphical representation of stereochemical configuration is made in accordance with IUPAC Recommendations (Pure Appl. Chem. (2006), 78(10), pp. 1897-1970). In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula I, II or A incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures thereof, are embraced within the scope of the invention.

(36) Diastereoisomeric mixtures can be separated into their individual diastereoisomers on the basis of their physico-chemical property differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Enantiomers can also be separated by use of chiral HPLC, or by chiral supercritical fluid chromatography. Also, some of the compounds of the invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.

(37) In particular, a skilled person will realize that even if the absolute stereochemistry of a particular stereoisomer (e.g., an enantiomer or diastereomer) of a molecule is not known, that particular stereoisomer can be distinguished from the other stereoisomers by use of other techniques (e.g., polarimetry, nuclear magnetic resonance spectroscopy, chromatography, and others identifiable to a skilled person). In particular, one exemplary method of distinguishing stereoisomers when the absolute stereochemistry of each stereoisomer is not known is chromatography, such as flash chromatography, medium pressure chromatography, high pressure liquid chromatography (HPLC), and/or supercritical fluid chromatography. In particular, two or more stereoisomers such as diastereomers can be separated and characterized by their retention times, which would be expected to be replicable by using the same chromatographic conditions (e.g., flow rate, column material, solvent systems/gradient profiles, and/or others identifiable to a skilled person). A skilled person will realize that even when the exact absolute or relative retention times of one or more stereoisomers is not replicated (e.g., due to slight variations in the chromatographic parameters and/or chromatographic equipment), a stereoisomer with a shorter retention time can be recognized and said to be “faster eluting,”, “earlier eluting” or having a “high Rf,” and a stereoisomer with a longer retention time can be recognized and said to be “slower eluting,” “later eluting or having a “low Rf.” A skilled person will realize that once two or more stereoisomers are distinguished by a technique such as chromatography, the absolute stereochemistry of the stereoisomers can be determined by techniques or combinations of techniques identifiable to a skilled person (e.g., X-ray crystallography, vibrational circular dichroism, nuclear magnetic resonance, total synthesis, and others identifiable to a skilled person).

(38) All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts and solvates of the compounds), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The use of the terms “salt”, “solvate”, and the like, is intended to equally apply to the salt and solvate of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, or racemates of the inventive compounds.

(39) The present invention includes all pharmaceutically acceptable isotopically enriched compounds. Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio, such as deuterium .sup.2H (or D) in place of hydrogen .sup.1H (or H), or use of .sup.13C enriched material in place of .sup.12C and the like. Similar substitutions can be employed for N, O, S and P. The use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention. These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.

(40) In an embodiment of the invention, there are provided pharmaceutical compositions including a therapeutically effective amount of at least one compound of the invention in a pharmaceutically acceptable carrier.

(41) The compounds of the invention and the pharmaceutical compositions comprising at least one compound of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving the FPR, such as FPR1 and/or FPR2.

(42) In a further embodiment of the invention, there are provided methods for treating disorders associated with FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2). Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or by administering a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the invention.

(43) More specifically, the present invention provides for: a compound of the invention for use in the treatment of a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); and/or a method of treating a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); wherein the disease or condition is an ocular inflammatory disease, including but not limited to: age-related macular degeneration, wet macular degeneration, dry macular degeneration, uveitis, dry eye, keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity, acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, uveitis, retinitis, choroiditis, such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi- and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, bone marrow transplant retinopathy, corneal wound healing, post-surgical corneal wound healing and/or inflammation, and post-cataract surgical inflammation; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, blepharitis, meibomian gland dysfunction (MDG), glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the retinal pigment epithelium (Perretti, Mauro et al. Pharmacology & Therapeutics 127 (2010) 175-188).

(44) In other embodiments, the present invention provides for: a compound of the invention for use in the treatment of a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); and/or a method of treating a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); wherein the disease or condition is a dermal inflammatory disease or condition, including, but not limited to: dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, disorders of pigmentation, alopecia, scarring and non-scarring forms.

(45) In yet other embodiments, the present invention provides for: a compound of the invention for use in the treatment of a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); and/or a method of treating a mammalian subject (including a human subject) having one or more diseases or conditions that are alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2); wherein the disease or condition is: stroke, coronary artery disease, a cardiovascular disorder, coronary artery disease, angina pectoris; or an obstructive airway disease; or a neurological disorder, Alzheimer's disease, neuroinflammation or pain; or an HIV-mediated retroviral infection; or an immunological disorder, arthritis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis; or sepsis; or inflammatory bowel disease (IBD), and/or IBD pain, Crohn's disease or ulcerative colitis; or asthma or an allergic disorder; or cachexia.

(46) In a further embodiment of the invention, the method of treating a disease or condition alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2), comprises administering to the subject in need of the treatment a therapeutically effective amount of at least one compound of the invention, or an enantiomer, diastereomer or tautomer thereof, or any mixture thereof in any ratio; or a pharmaceutically acceptable salt of any one of the foregoing; thereby treating the disease or condition.

(47) In a further embodiment of the invention, the method of treating a disease or condition alleviated by FPR modulation (such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2), comprises administering to the subject in need of the treatment a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the invention, or an enantiomer, diastereomer or tautomer thereof, or any mixture thereof in any ratio; or a pharmaceutically acceptable salt of any one of the foregoing; thereby treating the disease or condition.

(48) In one embodiment, the invention provides for a method of treating a disease or condition in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a compound of Formula I, II or A, to the subject (or a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, II or A to the subject), thereby treating the disease or condition. In one embodiment, the method comprises administering a compound of Formula I. In another embodiment, the method comprises administering a compound of Formula II. In another embodiment, the method comprises administering a compound of Formula A.

(49) In a further embodiment, the disease or condition is an ocular inflammatory disease or condition. In a further embodiment, the disease or condition is an ocular inflammatory disease or condition selected from the group consisting of: age-related macular degeneration, wet macular degeneration, dry macular degeneration, uveitis, dry eye, keratitis, allergic eye disease and conditions affecting the posterior part of the eye, such as maculopathies and retinal degeneration including non-exudative age related macular degeneration, exudative age related macular degeneration, choroidal neovascularization, diabetic retinopathy (proliferative), retinopathy of prematurity, acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema; infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, and choroiditis such as acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, infectious (syphilis, lyme, tuberculosis, toxoplasmosis), intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi- and Harada syndrome; vascular diseases/exudative diseases such as retinal arterial occlusive disease, central retinal vein occlusion, cystoids macular edema, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy and other hemoglobinopathies, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, conditions caused by laser, conditions caused by photodynamic therapy, photocoagulation, hypoperfusion during surgery, radiation retinopathy, bone marrow transplant retinopathy, post-surgical corneal wound healing or inflammation, and post-cataract surgical inflammation; proliferative disorders such as proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors, and miscellaneous other diseases affecting the posterior part of the eye such as punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, and acute retinal pigment epitheliitis, systemic inflammatory diseases such as stroke, coronary artery disease, obstructive airway diseases, HIV-mediated retroviral infections, cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus, psoriasis, CNS disorders such as Alzheimer's disease, arthritis, sepsis, inflammatory bowel disease, cachexia, angina pectoris, post-surgical corneal inflammation, blepharitis, MGD, dermal wound healing, corneal wound healing burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, viral warts, photoaging rheumatoid arthritis and related inflammatory disorders, alopecia, glaucoma, branch vein occlusion, Best's vitelliform macular degeneration, retinitis pigmentosa, proliferative vitreoretinopathy (PVR), and any other degenerative disease of either the photoreceptors or the retinal pigment epithelium. In a further embodiment, the ocular inflammatory disease or condition is selected from the group consisting of: dry eye, a post-surgical corneal wound, post-surgical corneal inflammation, and post-cataract surgical inflammation.

(50) In a further embodiment, there is provided the method of treating the disease or condition associated with FPR modulation, such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2, wherein the disease or condition is a dermal inflammatory disease or condition. In a further embodiment, the dermal inflammatory disease or condition is selected from the group consisting of: a dermal wound, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, disorders of pigmentation, alopecia, scarring and non-scarring forms. In a further embodiment, the dermal inflammatory disease or condition is psoriasis or rosacea.

(51) In a further embodiment, there is provided the method of treating the disease or condition associated with FPR modulation, such as FPR1 and FPR2 agonism, or FPR1 agonism, or selective agonism of FPR1 relative to FPR2, wherein the disease or condition is stroke, coronary artery disease, a cardiovascular disorder, coronary artery disease or angina pectoris; or an obstructive airway disease; or a neurological disorder, Alzheimer's disease, neuroinflammation or pain; or an HIV-mediated retroviral infection; or an immunological disorder, arthritis, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis; or sepsis; or inflammatory bowel disease or ulcerative colitis; or asthma or an allergic disorder; or cachexia. In one embodiment, the disease or condition is rheumatoid arthritis. In one embodiment, the disease or condition is multiple sclerosis. In another embodiment, the disease or condition is inflammatory bowel disease. In one embodiment, the disease or condition is ulcerative colitis.

(52) In one embodiment, there is provided the method of any one of the preceding embodiments, wherein the subject is a human.

(53) The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the subject/patient, the patient's general physical condition, the cause of the condition, and the route of administration.

(54) The subject will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back of the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.

(55) In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase “pharmaceutically acceptable” means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

(56) Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains a therapeutically effective amount of one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition, auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

(57) Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate, (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

(58) In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

(59) The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

(60) Pharmaceutical compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions. Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.

(61) For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential. The formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants. Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.

(62) Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

(63) Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

(64) In a similar manner an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

(65) Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.

(66) The ingredients are usually used in the following amounts:

(67) TABLE-US-00001 Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative 0-0.10 vehicle 0-40 tonicity adjustor 0-10 buffer 0.01-10 pH adjustor q.s. pH 4.5-7.8 antioxidant as needed surfactant as needed purified water to make 100%

(68) The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated, the selection of the appropriate dose is well within the knowledge of the skilled artisan.

(69) The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye. Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution. One package may contain one or more unit doses. Preservative-free solutions are often formulated in non-resalable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops. The volume of one drop usually is about 20-35 microliters.

(70) The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

(71) Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.

(72) In one embodiment, the invention provides for a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound of Formula I, II or A, and a pharmaceutically acceptable carrier. In a further embodiment, there is provided the pharmaceutical composition for use in treating an inflammatory disease or condition in a subject in need of such treatment, wherein the disease or condition is an ocular inflammatory disease or condition, or a dermal inflammatory disease or condition.

(73) Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent.

(74) The following are non-limiting embodiments of the invention.

(75) In embodiment (1), there is provided a compound of Formula I:

(76) ##STR00025##
wherein: W is —COOH, —C(O)OR.sup.a, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid, boronic acid or Het.sup.1; wherein R.sup.a is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, halogen, —OC.sub.1-8 alkyl and —(OC.sub.1-8 alkylene).sub.q-OC.sub.1-8 alkyl, wherein q is 1, 2, 3, 4, 5 or 6; and wherein Het.sup.1 is a 5-membered heteroaryl optionally substituted with one or more halogen, unsubstituted C.sub.1-6 alkyl, —C.sub.1-6 haloalkyl, —OC.sub.1-6alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl) or —(CH.sub.2).sub.1-6NR.sup.14R.sup.15; R.sup.1 is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-6 alkyl), —NR.sup.16R.sup.17, guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-6 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, and optionally substituted heterocycle; R.sup.2a is H, and R.sup.2 is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-s alkyl), —NR.sup.16R.sup.17, urea (—NHC(═O)NH.sub.2), guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-8 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, and optionally substituted heterocycle; or R.sup.2 and R.sup.2a form an optionally substituted C.sub.3-8 cycloalkyl or an optionally substituted C.sub.3-8 cycloalkenyl; R.sup.3 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.4 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.1; R.sup.5 is optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.13 or —OR.sup.13; R.sup.6 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.1; R.sup.7 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.1; R.sup.8 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.9 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.10 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.11 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.12 is H or optionally substituted C.sub.1-3 alkyl; R.sup.13 is H, optionally substituted C.sub.1-8 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-3 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.14 is C.sub.1-6 alkyl; R.sup.15 is C.sub.1-6 alkyl; R.sup.16 is C.sub.1-6 alkyl; R.sup.17 is C.sub.1-6 alkyl; R.sup.x is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; k is 0, 1 or 2; each m is independently 1 or 2; and either n is 0, p is 1 and R.sup.1 is absent, or n is 1, p is 0 and R.sup.2 is absent;
provided that when p is 0, then R.sup.2a is H;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(77) In embodiment (2), there is provided the compound of embodiment (1), wherein W is —OOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole; preferably, W is COOH or unsubstituted tetrazole.

(78) In embodiment (3), there is provided the compound of embodiment (1) or (2), wherein k is 0.

(79) In embodiment (4), there is provided the compound of embodiment (1) or (2), wherein k is 1.

(80) In embodiment (5), there is provided the compound of embodiment (1) or (2), wherein n is 0, p is 1, k is 0, and R.sup.2a is H, having the following structure:

(81) ##STR00026##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(82) In embodiment (6), there is provided the compound of embodiment (1) or (2), wherein n is 0, p is 1, k is 1, and R.sup.2a is H, having the following structure:

(83) ##STR00027##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(84) In embodiment (7), there is provided the compound of embodiment (1) or (2), wherein n is 1, p is 0, k is 0, and R.sup.2a is H, having the following structure:

(85) ##STR00028##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(86) In embodiment (8), there is provided the compound of embodiment (1) or (2), wherein n is 1, p is 0, k is 1, and R.sup.2a is H, having the following structure:

(87) ##STR00029##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(88) In embodiment (9), there is provided the compound of embodiment (1) or (2), wherein n is 0, p is 1, k is 0, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, the compound having the following structure:

(89) ##STR00030##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(90) In embodiment (10), there is provided the compound of embodiment (1) or (2), wherein n is 0, p is 1, k is 1, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, the compound having the following structure:

(91) ##STR00031##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(92) In embodiment (11), there is provided the compound of embodiment (9) or (10), wherein A is an optionally substituted C.sub.5-8 cycloalkyl; preferably, A is an unsubstituted C.sub.5-8 cycloalkyl.

(93) In embodiment (12), there is provided the compound of any one of embodiments (1) through (4), wherein R.sup.2a is H.

(94) In embodiment (13), there is provided the compound of any one of embodiments (1) through (8), wherein n is 1 and R.sup.1 is unsubstituted C.sub.1-6 alkyl, or p is 1 and R.sup.2 is unsubstituted C.sub.1-6 alkyl.

(95) In embodiment (14), there is provided the compound of embodiment (13), wherein R.sup.1 or R.sup.2 is unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl; preferably, isobutyl.

(96) In embodiment (15), there is provided the compound of embodiment (14), wherein R.sup.1 or R.sup.2 has the following structure:

(97) ##STR00032##

(98) In embodiment (16), there is provided the compound of any one of the preceding embodiments, wherein R.sup.5 is C.sub.1-6 haloalkyl or halogen; or is C.sub.1-6 haloalkyl, F, Cl or Br; or is C.sub.1-6 fluoroalkyl or Br; or is C.sub.1-6 perfluoroalkyl or Br; or is —CF.sub.3 or Br; or is —CF.sub.3; or is Br.

(99) In embodiment (17), there is provided the compound of any one of embodiments (1) through (8), wherein:

(100) n is 1 and R.sup.1 is unsubstituted C.sub.1-6 alkyl, or p is 1 and R.sup.2 is unsubstituted C.sub.1-6 alkyl;

(101) R.sup.3 is H or F;

(102) R.sup.4 is H;

(103) R.sup.5 is C.sub.1-6 haloalkyl or halogen;

(104) R.sup.6 is H; and

(105) R.sup.7 is H or F.

(106) In embodiment (18), there is provided the compound of any one of embodiments (1) through (8), wherein:

(107) n is 1 and R.sup.1 is unsubstituted C.sub.1-6 alkyl, or p is 1 and R.sup.2 is unsubstituted C.sub.1-6 alkyl;

(108) R.sup.3 is H;

(109) R.sup.4 is H;

(110) R.sup.5 is —CF.sub.3, fluorine, chlorine or bromine;

(111) R.sup.6 is H; and

(112) R.sup.7 is H.

(113) In embodiment (19), there is provided the compound of any one of embodiments (1) through (8), wherein:

(114) n is 1 and R.sup.1 is unsubstituted n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl, or p is 1 and R.sup.2 is unsubstituted n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl;

(115) R.sup.3 is H;

(116) R.sup.4 is H;

(117) R.sup.5 is —CF.sub.3, chlorine or bromine;

(118) R.sup.6 is H; and

(119) R.sup.7 is H.

(120) In embodiment (20), there is provided the compound of any one of embodiments (1) through (8), wherein:

(121) n is 1 and R.sup.1 is unsubstituted isobutyl, or p is 1 and R.sup.2 is unsubstituted isobutyl;

(122) R.sup.3 is H;

(123) R.sup.4 is H;

(124) R.sup.5 is bromine;

(125) R.sup.6 is H; and

(126) R.sup.7 is H.

(127) In embodiment (21), there is provided the compound of any one of the preceding embodiments, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or unsubstituted Het.sup.1.

(128) In embodiment (22), there is provided the compound of embodiment (21), wherein W is —COOH, sulfonic acid or tetrazole.

(129) In embodiment (23), there is provided the compound of any one of the preceding embodiments, wherein W is —C(O)OR.sup.a; preferably, R.sup.a is unsubstituted C.sub.1-6 alkyl; optionally, the compound is a prodrug, wherein the ester is hydrolyzed in vivo to provide the corresponding carboxylic acid.

(130) In embodiment (24), there is provided the compound of embodiment (1) or (2), wherein k is 0, R.sup.2a is H, R.sup.x is H or methyl, and either n is 1 and R.sup.1 is unsubstituted C.sub.1-6 alkyl, or p is 1 and R.sup.2 is C.sub.1-6 alkyl.

(131) In embodiment (25), there is provided the compound of embodiment (24), wherein n is 1 and R.sup.1 is isobutyl, or p is 1 and R.sup.2 is isobutyl.

(132) In embodiment (26), there is provided the compound of embodiment (24) or (25), wherein R.sup.5 is —CF.sub.3 or Br.

(133) In embodiment (27), there is provided the compound of embodiment (25) or (26), wherein each of R.sup.3, R.sup.4, R.sup.6 and R.sup.7 is independently selected from H and F, and W is —COOH or tetrazole.

(134) In embodiment (28), there is provided a compound selected from the group consisting of:

(135) ##STR00033##
and mixtures of enantiomers thereof;
and individual enantiomers or diastereoisomers thereof;
and pharmaceutically acceptable salts thereof;
preferably, the compound is:

(136) ##STR00034##
or a mixture of enantiomers of one of the foregoing,
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt thereof.

(137) In embodiment (29), there is provided a pharmaceutical composition comprising a compound of any one of embodiments (1) through (28) and a pharmaceutically acceptable excipient.

(138) In embodiment (30), there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of embodiments (1) through (28), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

(139) In embodiment (31), there is provided the pharmaceutical composition of embodiment (29) or (30), wherein the pharmaceutically acceptable excipient is an ophthalmically acceptable excipient.

(140) In embodiment (32), there is provided a method of treating a disease or condition associated with FPR modulation in a subject in need thereof, the method comprising administering to the subject (a) a therapeutically effective amount of a compound of any one of embodiments (1) through (28); or (b) a pharmaceutical composition of any one of embodiments (29) through (31), thereby treating the disease or condition.

(141) In embodiment (33), there is provided the method of embodiment (32), wherein the disease or condition is an ocular inflammatory disease or condition, and the method treats the condition.

(142) In embodiment (34), there is provided the method of embodiment (33), wherein the disease or condition is dry eye.

(143) In embodiment (35), there is provided the method of embodiment (33), wherein the disease or condition is suppressed tear production, and the method results in the enhancement of tear production; in a further embodiment, the suppressed tear production is due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye disease).

(144) In embodiment (36), there is provided the method of embodiment (32), wherein the disease or condition is a dermal inflammatory disease or condition, and the method reduces the inflammation.

(145) In embodiment (37), there is provided the method of embodiment (36), wherein the disease or condition is psoriasis or rosacea.

(146) In embodiment (38), there is provided the method of embodiment (32), wherein the disease or condition is a gastrointestinal disease or condition, and the method treats the condition; preferably, the disease or condition is inflammatory bowel disease, Crohn's disease or ulcerative colitis.

(147) In embodiment (39), there is provided the method of embodiment (32) or (33), wherein the compound is administered to the subject topically, orally, systemically or via an implant, such as an ocular implant.

(148) In embodiment (40), there is provided the method of any one of embodiments (32) through (39), wherein the subject is a human.

(149) In embodiment (A1), there is provided a method of treating a disease or condition associated with FPR receptor modulation in a subject in need thereof, the method comprising administering to the subject a compound of Formula A:

(150) ##STR00035##
wherein: W is —OOH, —C(O)OR.sup.a, —C(O)NH.sub.2, —C(O)NH(C.sub.1-6 alkyl), —C(O)N—NR.sup.16R.sup.17, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid, boronic acid or Het.sup.1; wherein R.sup.a is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, halogen, —OC.sub.1-8 alkyl and —(OC.sub.1-8 alkylene).sub.q-OC.sub.1-8 alkyl, wherein q is 1, 2, 3, 4, 5 or 6; and wherein Het.sup.1 is a 5-membered heteroaryl optionally substituted with one or more halogen, unsubstituted C.sub.1-6 alkyl, —C.sub.1-6 haloalkyl, —OC.sub.1-6alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl) or —(CH.sub.2).sub.1-6NR.sup.14R.sup.15; R.sup.2a is H, and R.sup.2 is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-6 alkyl), —NR.sup.16R.sup.17, urea (—NHC(═O)NH.sub.2), guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-6 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, and optionally substituted heterocycle; or R.sup.2a and R.sup.2 form an optionally substituted C.sub.3-8 cycloalkyl or an optionally substituted C.sub.3-8 cycloalkenyl; R.sup.3 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.4 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.11; R.sup.5 is optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.13 or —OR.sup.13; R.sup.6 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.11; R.sup.7 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.1; R.sup.8 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.9 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.10 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.11 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.12 is H or optionally substituted C.sub.1-8 alkyl; R.sup.13 is H, optionally substituted C.sub.1-8 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.14 is C.sub.1-6 alkyl; R.sup.15 is C.sub.1-6 alkyl; R.sup.16 is C.sub.1-6 alkyl; R.sup.17 is C.sub.1-6 alkyl; k is 0, 1 or 2; and each m is independently 1 or 2;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(151) In embodiment (A2), there is provided the method according to embodiment (A1), wherein the method comprises administering to the subject a therapeutically effective amount of the compound of embodiment (A1), or a pharmaceutical composition comprising a therapeutically effective amount of the compound of embodiment (A1), thereby treating the disease or condition.

(152) In embodiment (A3), there is provided the method according to embodiment (A1) or (A2), wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole; preferably, W is —COOH or —S(O).sub.3H.

(153) In embodiment (A4), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 0.

(154) In embodiment (A5), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 1.

(155) In embodiment (A6), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 0, and R.sup.2a is H, and the compound has the following structure:

(156) ##STR00036##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(157) In embodiment (A7), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 1, and R.sup.2a is H, and the compound has the following structure:

(158) ##STR00037##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(159) In embodiment (A8), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 0, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, and the compound has the following structure:

(160) ##STR00038##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(161) In embodiment (A9), there is provided the method according to embodiment (A1), (A2) or (A3), wherein k is 1, and R.sup.2 and R.sup.2a form a hydrocarbon ring A, wherein A is optionally substituted C.sub.3-8 cycloalkyl or optionally substituted C.sub.3-8 cycloalkenyl, and the compound has the following structure:

(162) ##STR00039##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(163) In embodiment (A10), there is provided the method according to embodiment (A8) or (A9), wherein A is an optionally substituted C.sub.5-8 cycloalkyl.

(164) In embodiment (A11), there is provided the method according to embodiment (A10), wherein A is an unsubstituted C.sub.5-8 cycloalkyl; preferably, A is unsubstituted C.sub.6 or C.sub.8 cycloalkyl.

(165) In embodiment (A12), there is provided the method according to any one of embodiments (A1) to (A11), wherein Het.sup.1 is unsubstituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole.

(166) In embodiment (A13), there is provided the method according to any one of embodiments (A1) through (A7), wherein R.sup.2a is H and R.sup.2 is unsubstituted C.sub.1-6 alkyl or benzyl.

(167) In embodiment (A14), there is provided the method according to embodiment (A13), wherein R.sup.2a is H and R.sup.2 is n-propyl, n-butyl, isobutyl or benzyl.

(168) In embodiment (A15), there is provided the method according to embodiment (A13), wherein R.sup.2a is H and R.sup.2 has the following structure:

(169) ##STR00040##

(170) In embodiment (A16), there is provided the method according to any one of the preceding embodiments, wherein R.sup.5 is C.sub.1-6 haloalkyl or halogen; or is C.sub.1-6 haloalkyl, F, Cl or Br; or is C.sub.1-6 fluoroalkyl or Br; or is C.sub.1-6 perfluoroalkyl or Br; or is —CF.sub.3 or Br; or is —CF.sub.3; or is Br.

(171) In embodiment (A17), there is provided the method according to any one of embodiments (A1) through (A7), wherein:

(172) R.sup.2a is H;

(173) R.sup.2 is unsubstituted C.sub.1-6 alkyl or benzyl;

(174) R.sup.3 is H or F;

(175) R.sup.4 is H;

(176) R.sup.5 is C.sub.1-6 haloalkyl or halogen;

(177) R.sup.6 is H; and

(178) R.sup.7 is H or F;

(179) preferably, W is not —C(O)OR.sup.a.

(180) In embodiment (A18), there is provided the method according to embodiment (A17), wherein R.sup.3 is H; R.sup.5 is —CF.sub.3, fluorine, chlorine or bromine; and R.sup.7 is H.

(181) In embodiment (A19), there is provided the method according to embodiment (A17), wherein R.sup.2 is unsubstituted n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl or benzyl; R.sup.5 is —CF.sub.3, chlorine or bromine; and R.sup.7 is H.

(182) In embodiment (A20), there is provided the method according to embodiment (A17), wherein R.sup.2 is unsubstituted n-propyl, isobutyl or benzyl.

(183) In embodiment (A21), there is provided the method according to any one of the preceding embodiments, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or unsubstituted Het.sup.1; wherein Het.sup.1 is selected from the group consisting of tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole, and is preferably tetrazole.

(184) In embodiment (A22), there is provided the method according to any one of the preceding embodiments, wherein W is —COOH or sulfonic acid.

(185) In embodiment (A23), there is provided the method according to embodiment (1), wherein W is —C(O)OR.sup.a; optionally, the compound is a prodrug, wherein the ester is hydrolyzed in vivo to provide the corresponding carboxylic acid; preferably:

(186) R.sup.a is unsubstituted C.sub.1-6 alkyl;

(187) R.sup.2a is H;

(188) R.sup.2 is unsubstituted C.sub.1-6 alkyl or benzyl;

(189) R.sup.3 is H or F;

(190) R.sup.4 is H;

(191) R.sup.5 is C.sub.1-6 haloalkyl or halogen;

(192) R.sup.6 is H; and

(193) R.sup.7 is H or F.

(194) In embodiment (A24), there is provided the method according to embodiment (A1) or (A2), wherein the compound is selected from the group consisting of:

(195) ##STR00041## ##STR00042## ##STR00043##
and mixtures of enantiomers thereof;
and individual enantiomers or diastereoisomer thereof;
and pharmaceutically acceptable salts thereof.

(196) In embodiment (A25), there is provided the method according to embodiment (A1) or (A2), wherein the compound is selected from the group consisting of:

(197) ##STR00044## ##STR00045##
and mixtures of enantiomers thereof;
and individual enantiomers or diastereoisomer thereof;
and pharmaceutically acceptable salts thereof.

(198) In embodiment (A26), there is provided the method according to embodiment (A1) or (A2), wherein the compound is selected from the group consisting of:

(199) ##STR00046##
and mixtures of enantiomers thereof;
and individual enantiomers or diastereoisomer thereof;
and pharmaceutically acceptable salts thereof.

(200) In embodiment (A27), there is provided the method according to embodiment (A1), (A2) or (A3), wherein the compound is selected from the group consisting of:

(201) ##STR00047##
and mixtures of two or more diastereomers thereof;
and mixture of enantiomers thereof;
and individual enantiomers or diastereoisomers thereof;
and pharmaceutically acceptable salts thereof.

(202) In embodiment (A28), there is provided the method according to embodiment (A1) or (A2), wherein the compound is selected from the group consisting of:

(203) ##STR00048##
and mixtures of enantiomers thereof;
and individual enantiomers and diastereomers thereof;
and pharmaceutically acceptable salts thereof.

(204) In embodiment (A29), there is provided the method any one of embodiments (A1) through (A28), wherein the disease or condition is an ocular inflammatory disease or condition, and the method treats the condition.

(205) In embodiment (A30), there is provided the method of embodiment (A29), wherein the disease or condition is dry eye.

(206) In embodiment (A31), there is provided the method of embodiment (A29), wherein the disease or condition is suppressed tear production, and the method results in the enhancement of tear production; in a further embodiment, the suppressed tear production is due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye disease).

(207) In embodiment (A32), there is provided the method of any one of embodiments (A1) through (A28), wherein the disease or condition is a dermal inflammatory disease or condition, and the method reduces the inflammation, thereby treating the disease or condition.

(208) In embodiment (A33), there is provided the method of embodiment (A32), wherein the disease or condition is psoriasis or rosacea.

(209) In embodiment (A34), there is provided the method of any one of embodiments (A1) through (A28), wherein the disease or condition is a gastrointestinal disease or condition, and the method treats the condition; preferably, the disease or condition is inflammatory bowel disease, Crohn's disease or ulcerative colitis.

(210) In embodiment (A35), there is provided the method of any one of embodiments (A1) through (A34), wherein the compound is administered to the subject topically, orally, systemically or via an implant, such as an ocular implant.

(211) In embodiment (A36), there is provided the method of any one of embodiments (A1) through (A35), wherein the subject is a human.

(212) In embodiment (A37), there is provided a compound selected from the group consisting of:

(213) ##STR00049##
and mixtures of two or more diastereomers thereof;
and mixture of enantiomers thereof;
and individual enantiomers or diastereoisomers thereof;
and pharmaceutically acceptable salts thereof.

(214) In embodiment (A38), there is provided a compound which is:

(215) ##STR00050##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salts of any one of the foregoing.

(216) In embodiment (B1), there is provided a compound of Formula II:

(217) ##STR00051##
wherein: W is —OOH, —C(O)OR.sup.a, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid, boronic acid or Het.sup.1; wherein R.sup.a is optionally substituted C.sub.1-6 alkyl, wherein said optional substituent is selected from the group consisting of —OH, halogen, —OC.sub.1-8 alkyl and —(OC.sub.1-8 alkylene).sub.q-OC.sub.1-8 alkyl, wherein q is 1, 2, 3, 4, 5 or 6; and wherein Het.sup.1 is a 5-membered heteroaryl optionally substituted with one or more halogen, unsubstituted C.sub.1-6 alkyl, —C.sub.1-6 haloalkyl, —OC.sub.1-6alkyl, —(CH.sub.2).sub.1-6OH, —(CH.sub.2).sub.1-6NH.sub.2, —(CH.sub.2).sub.1-6NH(C.sub.1-6 alkyl) or —(CH.sub.2).sub.1-6NR.sup.14R.sup.15 R.sup.2 is (a) unsubstituted C.sub.2-6 alkyl, (b) —CH.sub.2—(C.sub.1-5 alkyl), wherein said C.sub.1-5 alkyl is optionally substituted with —OH, —SH, —OC.sub.1-6 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-6 alkyl), —NR.sup.16R.sup.17, urea (—NHC(═O)NH.sub.2), guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-6 alkyl, —C(O)NH.sub.2, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-3 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle, or (c) —CH.sub.2R.sup.16, wherein R.sup.16 is an optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-3 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.3 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.4 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.1; R.sup.5 is optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.13 or —OR.sup.13; R.sup.6 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, halogen, —S(O).sub.mR.sup.10 or —C(O)R.sup.1; R.sup.7 is H, optionally substituted C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl, optionally substituted heterocycle, halogen, —NR.sup.8R.sup.9, —S(O).sub.mR.sup.10, —C(O)R.sup.11, —SR.sup.12 or —OR.sup.12; R.sup.8 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.9 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; R.sup.10 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.11 is —OH, optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-10 aryl; R.sup.12 is H or optionally substituted C.sub.1-8 alkyl; R.sup.13 is H, optionally substituted C.sub.1-8 alkyl, optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; and R.sup.14 is C.sub.1-6 alkyl; R.sup.15 is C.sub.1-6 alkyl; R.sup.16 is C.sub.1-6 alkyl; R.sup.17 is C.sub.1-6 alkyl;
each m is independently 1 or 2;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(218) In embodiment (B2), there is provided the compound of embodiment (B1), wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole; preferably, W is —COOH or sulfonic acid.

(219) In embodiment (B3), there is provided the compound of embodiment (B1) or (B2), wherein R.sup.2 is unsubstituted C.sub.2-6 alkyl.

(220) In embodiment (B4), there is provided the compound of embodiment (B1), (B2) or (B3), wherein R.sup.2 is unsubstituted ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl.

(221) In embodiment (B5), there is provided the compound of any one of the preceding embodiments, wherein R.sup.2 has the following structure:

(222) ##STR00052##

(223) In embodiment (B6), there is provided the compound of embodiment (B1) or (B2), wherein R.sup.2 is —CH.sub.2—(C.sub.1-5 alkyl), wherein said C.sub.1-5 alkyl is optionally substituted with —OH, —SH, —OC.sub.1-8 alkyl, —SC.sub.1-6 alkyl, —NH.sub.2, —NH(C.sub.1-s alkyl), —NR.sup.16R.sup.17, urea (—NHC(═O)NH.sub.2), guanido (—NHC(═NH)NH.sub.2), —COOH, —C(O)OC.sub.1-8 alkyl or —C(O)NH.sub.2; preferably, R.sup.2 is unsubstituted —CH.sub.2—(C.sub.1-5alkyl).

(224) In embodiment (B7), there is provided the compound of (B1) or (B2), wherein R.sup.2 is —CH.sub.2R.sup.16, wherein R.sup.16 is optionally substituted C.sub.3-8 cycloalkyl, optionally substituted C.sub.3-8 cycloalkenyl, optionally substituted C.sub.6-10 aryl or optionally substituted heterocycle; preferably, R.sup.2 is benzyl.

(225) In embodiment (B8), there is provided the compound of any one of the preceding embodiments, wherein R.sup.5 is C.sub.1-6 haloalkyl or halogen; or is C.sub.1-6 haloalkyl, F, Cl or Br; or is C.sub.1-6 fluoroalkyl or Br; or is C.sub.1-6 perfluoroalkyl or Br; or is —CF.sub.3 or Br; or is —CF.sub.3; or is Br.

(226) In embodiment (B9), there is provided the compound of embodiment (B1) or (B2), wherein:

(227) R.sup.2 is unsubstituted C.sub.2-6 alkyl;

(228) R.sup.3 is H or F;

(229) R.sup.4 is H;

(230) R.sup.5 is C.sub.1-6 haloalkyl or halogen;

(231) R.sup.6 is H; and

(232) R.sup.7 is H or F.

(233) In embodiment (B10), there is provided the compound of embodiment (B9), wherein:

(234) R.sup.2 is unsubstituted C.sub.2-6 alkyl;

(235) R.sup.3 is H;

(236) R.sup.4 is H;

(237) R.sup.5 is —CF.sub.3, fluorine, chlorine or bromine;

(238) R.sup.6 is H; and

(239) R.sup.7 is H.

(240) In embodiment (B11), there is provided the compound of embodiment (B9), wherein:

(241) R.sup.2 is unsubstituted n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl;

(242) R.sup.3 is H;

(243) R.sup.4 is H;

(244) R.sup.5 is —CF.sub.3, chlorine or bromine;

(245) R.sup.6 is H; and

(246) R.sup.7 is H.

(247) In embodiment (B12), there is provided the compound of embodiment (B9), wherein:

(248) R.sup.2 is unsubstituted isobutyl;

(249) R.sup.3 is H;

(250) R.sup.4 is H;

(251) R.sup.5 is bromine;

(252) R.sup.6 is H; and

(253) R.sup.7 is H.

(254) In embodiment (B13), there is provided the compound of any one of the preceding embodiments, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or unsubstituted Het.sup.1.

(255) In embodiment (B14), there is provided the compound of any one of the preceding embodiments, wherein W is —COOH, sulfonic acid or tetrazole.

(256) In embodiment (B15), there is provided the compound of any one of the preceding embodiments, wherein W is —COOH or —SO.sub.3H.

(257) In embodiment (B16), there is provided the compound of any one of the preceding embodiments, wherein W is —SO.sub.3H.

(258) In embodiment (B17), there is provided the compound of embodiment (B1) or (B2), wherein Het.sup.1 is an unsubstituted 5-membered heteroaryl; such as an unsubstituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole.

(259) In embodiment (B18), there is provided the compound of embodiment (B1) or (B2), wherein the compound has the following structure:

(260) ##STR00053##
or an individual enantiomer thereof;
or a mixture of enantiomers thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(261) In embodiment (B19), there is provided a pharmaceutical composition comprising a compound of any one of embodiments (B1) through (B18) and a pharmaceutically acceptable excipient.

(262) In embodiment (B20), there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of embodiments (B1) through (B18), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

(263) In embodiment (B21), there is provided the pharmaceutical composition of embodiment (B19) or (B20), wherein the pharmaceutically acceptable excipient is an ophthalmically acceptable excipient.

(264) In embodiment (B22), there is provided a method of treating a disease or condition associated with FPR modulation in a subject in need thereof, the method comprising administering to the subject (a) a therapeutically effective amount of a compound of any one of embodiments (B1) through (B18); or (b) a pharmaceutical composition of any one of embodiments (B19) through (B21), thereby treating the disease or condition.

(265) In embodiment (B23), there is provided the method of embodiment (B22), wherein the disease or condition is an ocular inflammatory disease or condition, and the method treats the condition.

(266) In embodiment (B24), there is provided the method of embodiment (B23), wherein the disease or condition is dry eye.

(267) In embodiment (B25), there is provided the method of embodiment (B23), wherein the disease or condition is suppressed tear production, and the method results in the enhancement of tear production; in a further embodiment, the suppressed tear production is due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye disease).

(268) In embodiment (B26), there is provided the method of embodiment (B22), wherein the disease or condition is a dermal inflammatory disease or condition, and the method reduces the inflammation, thereby treating the disease or condition.

(269) In embodiment (B27), there is provided the method of embodiment (B26), wherein the disease or condition is psoriasis or rosacea.

(270) In embodiment (B28), there is provided the method of embodiment (B22), wherein the disease or condition is a gastrointestinal disease or condition, and the method treats the condition; preferably, the disease or condition is inflammatory bowel disease, Crohn's disease or ulcerative colitis.

(271) In embodiment (B29), there is provided the method of embodiment (B22), wherein the compound is administered to the subject topically, orally, systemically or via an implant, such as an ocular implant.

(272) In embodiment (B30), there is provided the method of any one of embodiments (B22) through (B29), wherein the subject is a human.

(273) In embodiment (C1), there is provided a method of selectively modulating an FPR1 receptor relative to an FPR2 receptor in a recipient, the method comprising administering a compound of Formula I, A or II, or a pharmaceutically acceptable salt thereof, to the recipient, wherein the compound exhibits at least 2-fold selectivity for FPR1 relative to FPR2, and wherein the selectivity is based on the ratio of the EC.sub.50 for agonizing FPR2 to the EC.sub.50 for agonizing FPR1 as measured in an in vitro, ex vitro and/or in vivo assay; provided that W is not —C(O)OR.sub.a; preferably, the compound is selected from the group consisting of: (a) a compound of Formula I, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is COOH or unsubstituted tetrazole); either n is 1, p is 0 and R.sup.1 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl), or p is 1, n is 0 and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl); R.sup.2a is H; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R.sup.x is H; and k is 0; (b) a compound of Formula A, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2a is H and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; or R.sup.2a and R.sup.2 form an unsubstituted C.sub.3-8 cycloalkyl (preferably C.sub.5-8 or C.sub.6-8 cycloalkyl); R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R.sup.x is H; and k is 0 or 1 (preferably, 0); and (c) a compound of Formula II, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; and k is 1;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof,
or a pharmaceutically acceptable salt of any one of the foregoing.

(274) In embodiment (C2), there is provided a method of embodiment (C1), wherein the recipient is a mammalian subject.

(275) In embodiment (C3), there is provided a method of embodiment (C2), wherein the subject is a human.

(276) In embodiment (C4), there is provided a method of embodiment (C1), wherein the recipient is a cell or tissue.

(277) In embodiment (C5), there is provided a method of embodiment (C4), wherein the compound is administered to the cell or tissue recipient in vitro.

(278) In embodiment (C6), there is provided a method of embodiment (C4), wherein the compound is administered to the cell or tissue recipient ex vivo.

(279) In embodiment (C7), there is provided the method of embodiment (C1), wherein the recipient is an in vitro FPR receptor assay system.

(280) In embodiment (C8), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 5-fold selectivity for FPR1 compared to FPR2.

(281) In embodiment (C9), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 10-fold selectivity for FPR1 compared to FPR2.

(282) In embodiment (C10), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 20-fold selectivity for FPR1 compared to FPR2.

(283) In embodiment (C11), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 50-fold selectivity for FPR1 compared to FPR2.

(284) In embodiment (C12), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 100-fold selectivity for FPR1 compared to FPR2.

(285) In embodiment (C13), there is provided the method of any one of embodiments (C1) through (C7), wherein the compound exhibits at least 200-fold selectivity for FPR1 compared to FPR2.

(286) In embodiment (C14), there is provided the method of embodiment (C1), wherein the compound is selected from the group consisting of:

(287) ##STR00054## ##STR00055##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any of the foregoing.

(288) In embodiment (C15), there is provided the method of embodiment (C1), wherein the compound is selected from the group consisting of:

(289) ##STR00056##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any of the foregoing.

(290) In embodiment (C16), there is provided the method of embodiment (C1), wherein the compound is:

(291) ##STR00057##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(292) In embodiment (C17), there is provided the method of embodiment (C1), wherein the compound is:

(293) ##STR00058##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(294) In embodiment (C18), there is provided the method of embodiment (C1), wherein the compound is:

(295) ##STR00059##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(296) In embodiment (C19), there is provided the method of embodiment (C1), wherein the compound is:

(297) ##STR00060##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(298) In embodiment (C20), there is provided the method of embodiment (C1), wherein the compound is:

(299) ##STR00061##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(300) In embodiment (C21), there is provided the method of embodiment (C1), wherein the compound is:

(301) ##STR00062##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(302) In embodiment (C21), there is provided the method of embodiment (C1), wherein the compound is:

(303) ##STR00063##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(304) In embodiment (D1), there is provided a method of screening for a substance that modulates an FPR receptor, the method comprising:

(305) a) contacting an FPR receptor with a test substance,

(306) b) determining the ability of the test substance to modulate the FPR receptor, and

(307) c) comparing the ability of the test substance to modulate the FPR receptor with the ability of a compound of Formula I, A or II, or a pharmaceutically acceptable salt thereof, to modulate an FPR receptor of the same subtype(s); provided that W is not —C(O)OR.sub.a; preferably, the compound is selected from the group consisting of: (a) the compound of Formula I, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is COOH or unsubstituted tetrazole); either n is 1, p is 0 and R.sup.1 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl), or p is 1, n is 0 and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl); R.sup.2a is H; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R.sup.x is H; and k is 0; (b) the compound of Formula A, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2a is H and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; or R.sup.2a and R.sup.2 form an unsubstituted C.sub.3-8 cycloalkyl (preferably C.sub.5-8 or C.sub.6-8 cycloalkyl); R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R is H; and k is 0 or 1 (preferably, 0); and (c) the compound of Formula II, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; and k is 1;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(308) In embodiment (D2), there is provided the method of embodiment (D1), wherein the FPR receptor is selected from a group of FPR receptor subtypes consisting of:

(309) (i) FPR1;

(310) (ii) FPR1 and FPR2;

(311) (iii) FPR1 and FPR3; and

(312) (iv) FPR1, FPR2 and FPR3.

(313) In embodiment (D3), there is provided the method of embodiment (D1) or (D2), wherein the compound serves as a control.

(314) In embodiment (D4), there is provided the method of any one of embodiments (D1) through (D3), wherein the method identifies the substance as an FPR modulator.

(315) In embodiment (D5), there is provided the method of any one of embodiments (D1) through (D4), wherein the determining of the ability of the test substance to modulate the FPR receptor comprises determining an increase or decrease in the FPR receptor activity level.

(316) In embodiment (D6), there is provided the method of embodiment (D5), wherein the increase or decrease in the FPR receptor activity level indicates that the substance is an FPR receptor agonist or antagonist, respectively.

(317) In embodiment (D7), there is provided the method of any one of embodiments (D1) through (D6), wherein the method indicates that the substance is a selective FPR1 receptor subtype agonist.

(318) In embodiment (D8), there is provided the method of any one of embodiments (D1) through (D6), wherein the method indicates that the substance is an FPR1 receptor subtype agonist and an FPR2 receptor subtype agonist.

(319) In embodiment (D9), there is provided the method of any one of embodiments (D1) through (D8), wherein the compound is selected from the group consisting of:

(320) ##STR00064##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any of the foregoing.

(321) In embodiment (D10), there is provided the method of embodiment (D9), wherein the compound is:

(322) ##STR00065##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(323) In embodiment (D11), there is provided the method of embodiment (D9), wherein the compound is:

(324) ##STR00066##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(325) In embodiment (D12), there is provided the method of embodiment (D9), wherein the compound is:

(326) ##STR00067##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(327) In embodiment (D13), there is provided the method of embodiment (D9), wherein the compound is:

(328) ##STR00068##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(329) In embodiment (D14), there is provided the method of embodiment (D9), wherein the compound is:

(330) ##STR00069##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(331) In embodiment (D15), there is provided the method of embodiment (D9), wherein the compound is:

(332) ##STR00070##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(333) In embodiment (D16), there is provided the method of embodiment (D9), wherein the compound is:

(334) ##STR00071##
or a mixture of enantiomers thereof;
or an individual enantiomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(335) In embodiment (E1), there is provided a use of a compound of Formula I, A or II, or a pharmaceutically acceptable salt thereof, in identifying a biochemical and/or pharmacological effect(s) of agonizing an FPR1 receptor in a cell or tissue; provided that W is not —C(O)OR.sub.a; preferably, the compound is selected from the group consisting of: (a) a compound of Formula I, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is COOH or unsubstituted tetrazole); either n is 1, p is 0 and R.sup.1 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl), or p is 1, n is 0 and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, isobutyl); R.sup.2a is H; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R is H; and k is 0; (b) a compound of Formula A, wherein: W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2a is H and R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; or R.sup.2a and R.sup.2 form an unsubstituted C.sub.3-8 cycloalkyl (preferably C.sub.5-8 or C.sub.6-8 cycloalkyl); R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; R is H; and k is 0 or 1 (preferably, 0); and (c) a compound of Formula II, wherein W is —COOH, sulfonate, sulfonic acid, phosphonate, phosphonic acid, phosphoric acid or Het.sup.1, wherein Het.sup.1 is optionally substituted tetrazole, imidazole, thiazole, oxazole, triazole, isoxazole, oxadiazole, thiadiazole, thiophene, pyrazole or pyrrole (preferably, W is —COOH or —S(O).sub.3H); R.sup.2 is unsubstituted C.sub.1-6 alkyl (preferably, n-propyl or isobutyl) or benzyl; R.sup.3 is H or F; R.sup.4 is H; R.sup.5 is C.sub.1-6 haloalkyl or halogen; R.sup.6 is H; R.sup.7 is H or F; and k is 1;
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any one of the foregoing.

(336) In embodiment (E2), there is provided a use of a compound of embodiment (E1), wherein the compound wherein the compound is selected from the group consisting of:

(337) ##STR00072##
or a mixture of two or more diastereomers thereof;
or a mixture of enantiomers thereof;
or an individual enantiomer or diastereoisomer thereof;
or a pharmaceutically acceptable salt of any of the foregoing.

(338) The present invention also concerns processes for preparing compounds of Formula I, II and/or Formula A.

(339) Synthetic schemes and examples set forth below illustrate how the compounds according to the invention can be made, and provide details of certain specific chemical transformations. The Examples are for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will be able to routinely modify and/or adapt the Scheme or Examples to synthesize any compound of the invention that falls within the scope of Formula I, II or A, and will appreciate that variations and modifications of the Examples can be made without exceeding the spirit or scope of the invention.

EXAMPLES

(340) All reagents, solvents and catalysts for which the synthesis is not described are purchased from chemical vendors such as 3B Scientific, Sigma Aldrich, Fluka, Bio-Blocks, Combi-blocks, TCI, VWR, Lancaster, Oakwood, Trans World Chemical, Alfa, Fisher, Maybridge, Frontier, Matrix, Ukrorgsynth, Toronto, Ryan Scientific, SiliCycle, Anaspec, Syn Chem, Chem-Impex, MIC-scientific, Ltd; however some known intermediates were prepared according to published procedures.

(341) Compound names were generated with ACDLab version 12.5; some intermediate and reagent names used in the Examples were generated with software such as Chem Bio Draw Ultra version 12.0, ACDLab version 12.5 or Auto Nom 2000 from MDL ISIS Draw 2.5 SP1.

(342) In general, characterization of the compounds was performed using NMR spectroscopy. NMR spectra were acquired on a 300 or 600 MHz Varian NMR spectrometer at room temperature. Chemical shifts are given in ppm referenced either to internal TMS or to the solvent signal. Usually, the compounds of the invention were purified by medium pressure liquid chromatography, unless noted otherwise.

(343) The following abbreviations are used herein: Ac acetate Boc tert-butyloxycarbonyl CD.sub.3OD deuterated methanol DCC N,N′-dicyclohexylcarbodiimide DCM dichloromethane DEA diethylamine DIEPA diisopropylethylamine EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Et.sub.3N triethylamine EtOAc ethyl acetate H.sub.2 hydrogen gas HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate HCO.sub.2H formic acid HOBt hydroxybenzotriazole HPLC high performance liquid chromatography MeOH methanol MPLC medium pressure liquid chromatography Na.sub.2SO.sub.4 sodium sulfate Pd/C palladium on carbon THE tetrahydrofuran TMS tetramethylsilane

(344) ##STR00073##

(345) ##STR00074##

(346) ##STR00075##

Example A—Synthesis of Intermediates

(347) ##STR00076##

Intermediate 1. Methyl 2-((2-((tert-butoxycarbonyl)amino)acetamido)methyl)-4-methylpentanoate

(348) ##STR00077##

(349) Intermediate 1 was prepared as outlined in Scheme A. Briefly, to a solution of methyl 2-(aminomethyl)-4-methyl pentanoate hydrochloride (300 mg, 1.53 mmol) and 20 mL of anhydrous dichloromethane at 25° C. was added DCC (316 mg, 1.53 mmol), and Boc-glycine (268 mg, 1.53 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting product was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (9:1) to yield Intermediate 1 as white solid. .sup.1H NMR (CD.sub.3OD, 600 MHz) δ: 3.76 (d, J=5.3 Hz, 2H), 3.69 (s, 3H), 3.48-3.54 (m, 1H), 3.32-3.39 (m, 1H), 2.69 (dd, J=7.0, 4.1 Hz, 1H), 1.59-1.63 (m, 2H), 1.45 (s, 9H), 1.36-1.38 (m, 1H), 0.91 (s, 3H), 0.90 (s, 3H).

Intermediate 2. Methyl 2-((2-aminoacetamido)methyl)-4-methylpentanoate

(350) ##STR00078##

(351) Intermediate 1 was prepared as outlined in Scheme A. Briefly, a solution of intermediate 1 (290 mg, 0.92 mmol) and 8 mL of formic acid was stirred at 25° C. for 4 hours. The resulting reaction was quenched with water (10 mL), and the product was extracted with EtOAc. The organic layer was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure to yield intermediate 7a as a white solid. .sup.1H NMR (CD.sub.3OD, 600 MHz) δ: 4.21 (m, 2H), 3.70 (d, J=5.3 Hz, 2H), 3.40 (s, 3H), 2.69 (m, 1H), 1.59-1.63 (m, 2H), 1.36-1.38 (m, 1H), 0.91 (s, 6H).

Example 1—Synthesis of Compounds 1 Through 6

Compound 1. Methyl 2-[({[(4-bromophenyl)amino]carbonyl}amino)methyl]-4-methylpentanoate

(352) ##STR00079##

(353) To a solution of methyl 2-(aminomethyl)-4-methylpentanoate hydrochloride (300 mg, 1.53 mmol) and 12 mL of methylene chloride at 25° C. was added 4-bromo-phenyl isocyanate (302 mg, 1.53 mmol) and triethylamine (0.27 mL, 1.99 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was concentrated and the residue was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (2:8) to yield compound 1 as white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.23-7.41 (m, 4H), 3.69 (s, 3H), 3.31-3.45 (m, 2H), 2.68-2.83 (m, 1H), 1.45-1.67 (m, 2H), 1.20-1.39 (m, 2H), 0.87-0.98 (m, 6H).

(354) Compounds 2, 3, 4, 5 and were prepared from the corresponding beta amino acid in a similar manner to the procedure described for Compound 1. The structures and physical characteristics of compounds 2, 3, 4, 5 and 6 are described in Table 1.

(355) TABLE-US-00002 TABLE 1 Cmpd. IUPAC name No. Structure .sup.1H NMR δ (ppm) 2 Methyl 4-methyl-2-{[({[4- White solid; .sup.1H NMR (CD.sub.3OD, (trifluoromethyl)phenyl]amino} 300 MHz) δ: 7.52 (s, 4H), 3.69 carbonyl)amino]methyl}pentanoate (s, 3H), 3.32-3.48 (m, 2H), 0 2.67-2.83 (m, 1H), 1.50-1.68 (m, 2H), 1.25-1.41 (m, 1H), 0.93 (d, J = 4.7 Hz, 6H). 3 Methyl 2-[({[(4- White solid; .sup.1H NMR (CD.sub.3OD, chlorophenyl)amino]carbonyl} 300 MHz) δ: 7.29-7.37 (m, 2H), amino)methyl]-4-methylpentanoate 7.15-7.25 (m, 2H), 3.69 (s, 3H), 3.37 (m, 2H), 2.69-2.82 (m, 1H), 1.48-1.68 (m, 2H), 1.26- 1.39 (m, 1H), 0.92 (dd, J = 6.2, 1.5 Hz, 6H). 4 Methyl 2[({[(4-bromo-2- White solid; .sup.1H NMR (CD.sub.3OD, fluorophenyl)amino]carbonyl}amino) 300 MHz) δ: 7.95 (t, J = 8.6 Hz, methyl]-4-methylpentanoate 1H), 7.27-7.33 (m, 1H), 7.23 (d, J = 8.8 Hz, 1H), 3.37-3.46 (m, 1H), 3.32-3.34 (m, 1H), 2.68- 2.80 (m, 1H), 1.49-1.66 (m, 2H), 1.25-1.39 (m, 1H), 0.92 (dd, J = 6.3, 1.9 Hz, 6H). 5 Methyl 2-[({[(4- White solid; .sup.1H NMR (CD.sub.3OD, methoxyphenyl)amino]carbonyl} 300 MHz) δ: 7.17-7.24 (m, 2H), amino)methyl]-4-methylpentanoate 6.79-6.87 (m, 2H), 3.75 (s, 3H), 3.69 (s, 3H), 3.33-3.42 (m, 1H), 3.25-3.29 (m, 1H), 2.69-2.80 (m, 1H), 1.48-1.66 (m, 2H), 1.25-1.36 (m, 1H), 0.92 (dd, J = 6.4, 2.1 Hz, 6H). 6 Methyl 4-methyl-2-{[({[4- White solid; .sup.1H NMR (CD.sub.3OD, (trifluoromethoxy)phenyl]amino} 300 MHz) δ: 7.42 (d, J = 9.1 Hz, carbonyl)amino]methyl}pentanoate 2H), 7.15 (d, J = 8.8 Hz, 2H), 3.69 (s, 3H), 3.34-3.45 (m, 2H), 2.66-2.82 (m, 1H), 1.46-1.70 (m, 2H), 1.31 (s, 1H), 0.86-0.97 (m, 6H).

Example 2—Synthesis of Compounds 7 Through 12

Compound 7. 2-[({[(4-Bromophenyl)amino]carbonyl}amino)methyl]-4-methylpentanoic acid

(356) ##STR00085##

(357) A solution of compound 1 (1.23 g, 3.44 mmol), 6N NaOH (3.44 mL, 20.6 mmol) and 15 mL of MeOH was stirred at 50° C. for 12 hours. The resulting mixture was quenched with 10% HCl (15 mL) to pH 2, then extracted with ethyl acetate. The organic layer was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated under reduced pressure. The residue was rinsed four times with acetone:hexane (2:98) to yield compound 7 as a white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.24-7.40 (m, 4H), 3.34-3.47 (m, 1H), 3.26 (m, 1H), 2.68 (tt, J=8.5, 5.6 Hz, 1H), 1.48-1.74 (m, 2H), 1.25-1.39 (m, 1H), 0.94 (dd, J=6.4, 0.9 Hz, 6H).

(358) Compounds 8, 9, 10, 11 and 12 were prepared from the corresponding urea derivative in a similar manner to the procedure described for compound 7. The structures and physical characteristics of compounds 8, 9, 10, 11 and 12 are described in Table 2.

(359) TABLE-US-00003 TABLE 2 Cmpd. IUPAC name No. Structure .sup.1H NMR δ (ppm) 8 4-Methyl-2-{[({[4- White solid; .sup.1H NMR (CD.sub.3OD, (trifluoromethyl)phenyl}amino} 300 MHz) δ: 7.52 (s, 4H), 3.32- carbonyl)amino]methyl}pentanoic 3.48 (m, 2H), 2.63-2.78 (m, acid 1H), 1.49-1.76 (m, 2H), 1.26- 1.39 (m, 1H), 0.95 (d, J = 6.2 Hz, 6H). 9 2-[({[(4- White solid, .sup.1H NMR (CD.sub.3OD, Chlorophenyl)amino]carbonyl} 300 MHz) δ: 7.31-7.38 (m, 2H), amino)methyl]-4-methylpentanoic acid 7.18-7.25 (m, 2H), 3.35-3.47 (m, 1H), 3.17-3.29 (m, 1H), 2.60-2.76 (m, 1H), 1.49-1.74 (m, 2H), 1.23-1.39 (m, 1H), 0.87-0.98 (m, 6H). 10 2[({[(4-Bromo-2- White solid, .sup.1H NMR (CD.sub.3OD, fluorophenyl)amino]carbonyl} 300 MHz) δ: 7.89-8.03 (m, 1H), amino)methyl]-4-methylpentanoic acid 7.29 (d, J = 10.5 Hz, 1H), 7.20- 7.25 (m, 1H), 3.35-3.46 (m, 1H), 3.18-3.29 (m, 1H), 2.68 (m, 1H), 1.49-1.74 (m, 2H), 1.25-1.39 (m, 1H), 0.94 (d, J = 6.4 Hz, 6H). 11 2-[({[(4- White solid, .sup.1H NMR (CD.sub.3OD, methoxyphenyl)amino]carbonyl} 300 MHz) δ: 7.21 (d, J = 9.1 Hz, amino)methyl]-4-methylpentanoic 2H), 6.83 (d, J = 9.1 Hz, 2H), acid 3.75 (s, 3H), 3.34-3.44 (m, 1H), 3.25 (m, 1H), 2.62-2.76 (m, 1H), 1.61-1.76 (m, 1H), 1.47-1.60 (m, 1H), 1.23-1.37 (m, 1H), 0.94 (d, J = 6.4 Hz, 6H). 12 4-Methyl-2-{[({[4- White solid, .sup.1H NMR (CD.sub.3OD, (trifluoromethoxy)phenyl]amino} 300 MHz) δ: 7.42 (d, J = 8.8 Hz, carbonyl)amino]methyl}pentanoic 2H), 7.14 (d, J = 8.2 Hz, 2H), acid 3.35-3.48 (m, 1H), 3.30 (m, 0 3H), 2.62-2.77 (m, 1H), 1.61- 1.77 (m, 1H), 1.47-1.60 (m, 1H), 1.32 (ddd, J = 13.5, 7.8, 6.0 Hz, 1H), 0.94 (d, J = 6.7 Hz, 6H).

Example 3—Synthesis of Compounds 13 Through 20

Compound 13. 2-((3-(4-Bromophenyl)ureido)methyl)-3-methylbutanoic acid

(360) ##STR00091##

(361) To a solution of 2-(aminomethyl)-3-methylbutanoic acid hydrochloride (200 mg, 1.19 mmol) and 14 mL of methylene chloride at 25° C. was added 4-bromo-phenyl isocyanate (236 mg, 1.19 mmol) and triethylamine (0.25 mL, 1.78 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was concentrated and the residue was purified by medium pressure liquid chromatography on silica gel using methanol:dichloromethane (1:9) to yield compound 13 as white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.23-7.45 (m, 4H), 3.52 (dd, J=13.6, 4.2 Hz, 1H), 3.31-3.35 (m, 1H), 2.33-2.54 (m, 1H), 1.91-2.10 (m, 1H), 0.95-1.10 (m, 6H).

(362) Compounds 14, 15, 16, 17, 18, 19 and 20 were prepared from the corresponding beta amino acid in a similar manner to the procedure described for compound 13. The structures and physical characteristics of compounds 14, 15, 16, 17, 18, 19 and 20 are described in Table 3.

(363) TABLE-US-00004 TABLE 3 Cmpd. IUPAC name No. Structure .sup.1H NMR δ (ppm) 14 2-((3-(4- White solid; .sup.1H NMR (CD.sub.3OD, Bromophenyl)ureido)methyl) 300 MHz) δ: 7.24-7.45 (m, 4H), pentanoic acid 3.32-3.49 (m, 2H), 2.53-2.67 (m, 1H), 1.55-1.70 (m, 1H), 1.45-1.54 (m, 1H), 1.33-1.45 (m, 2H), 0.88- 1.02 (m, 3H). 15 2-Benzyl-3-(3-(4- White solid; .sup.1H NMR (CD.sub.3OD, bromophenyl)ureido)propanoic 300 MHz) δ: 7.14-7.39 (m, 9H), acid 3.32-3.49 (m, 2H), 2.80-3.02 (m, 3H). 16 3-(3-(4-Bromophenyl)ureido)-2- White solid; .sup.1H NMR (CD.sub.3OD, methylpropanoic acid 300 MHz) δ: 7.22-7.44 (m, 4H), 3.35 (d, J = 6.4 Hz, 2H), 2.66 (dq, J = 13.7, 6.9 Hz, 1H), 1.18 (d, J = 7.3 Hz, 3H). 17 2-((3-(4-Bromophenyl)ureido) White solid; .sup.1H NMR (CD.sub.3OD, methyl)butanoic acid 300 MHz) δ: 7.23-7.43 (m, 4H), 3.32-3.49 (m, 2H), 2.46-2.60 (m, 1H), 1.50-1.74 (m, 2H), 0.92-1.05 (m, 3H). 18 (1R*,2R*)-2-(3-(4- White solid; [α]D = 0, Bromophenyl)ureido)cyclohexane c = 1.00, DMF, .sup.1H NMR (CD.sub.3OD, carboxylic acid 600 MHz) δ: 7.32-7.36 (m, 2H), 7.25-7.29 (m, 2H), 3.81 (td, J = 11.0, 3.8 Hz, 1H), 2.27 (td, J = 11.2, 3.5 Hz, 1H), 2.01-2.06 (m, 1H), 1.95-2.00 (m, 1H), 1.71- 1.79 (m, 2H), 1.58 (qd, J = 12.7, 3.5 Hz, 1H), 1.37-1.46 (m, 1H), 1.22-1.32 (m, 2H). 19 (1R*,2S*)-2-(3-(4- White solid; [α]D = 0, Bromophenyl)ureido)cyclohexane c = 1.00, DMF, .sup.1H NMR (CD.sub.3OD, carboxylic acid 600 MHz) δ: 7.32-7.36 (m, 2H), 7.23-7.30 (m 2H), 3.81 (td, J = 10.9, 4.1 Hz, 1H), 2.28 (td, J = 11.2, 3.5 Hz, 1H), 1.96-2.06 (m, 2H), 1.72-1.80 (m, 2H), 1.54- 1.63 (m, 1H), 1.36-1.48 (m, 1H), 1.23-1.33 (m, 2H). 20 2-(3-(4- White solid; .sup.1H NMR (CD.sub.3OD, Bromophenyl)ureido)cyclooctane 600 MHz) δ: 7.32-7.39 (m, 2H), carboxylic acid 7.25-7.30 (m, 2H), 4.34 (dt, J = 10.4, 3.9 Hz, 1H), 2.86 (dt, J = 10.0, 4.1 Hz, 1H), 1.96-2.02 (m, 1H), 1.83-1.94 (m, 2H), 1.74- 1.81 (m, 2H), 1.58-1.71 (m, 7H).

Example 4—Synthesis of Compound 21

Compound 21. 1-(3-(4-Bromophenyl)ureido)-5-methylhexane-3-sulfonic acid

(364) ##STR00099##

(365) To a solution of 1-amino-5-methylhexane 3-sulfonic acid (150 mg, 0.77 mmol) and 8 mL of methylene chloride at 25° C. was added 4-bromo-phenyl isocyanate (152 mg, 0.77 mmol) and triethylamine (0.16 mL, 1.15 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was quenched with 10% HCl (1 mL) to pH 2 then extracted with ethyl acetate. The organic layer was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by medium pressure liquid chromatography on silica gel using methanol:dichloromethane (15:85) to yield compound 21 as white solid. .sup.1H NMR (CD.sub.3OD, 600 MHz) δ: 7.24-7.43 (m, 4H), 3.41 (s, 2H), 2.79 (dd, J=7.3, 4.4 Hz, 1H), 1.95-2.05 (m, 1H), 1.77-1.93 (m, 3H), 1.43 (t, J=8.5 Hz, 1H), 0.94 (d, J=6.5 Hz, 3H), 0.90 (d, J=5.9 Hz, 3H).

(366) ##STR00100##

Example 5—Synthesis of Compounds 31 Through 39

Compound 31. t-Butyl ({2-[({[(4 bromophenyl)amino]carbonyl}amino)methyl]-4-methylpentanoyl}amino)acetate

(367) ##STR00101##

(368) To a solution of compound 1 (168 mg, 0.49 mmol) and 20 mL of anhydrous dichloromethane at 25° C. was added DCC (101 mg, 0.49 mmol), and glycine tert-butyl ester (71 mg, 0.87 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was filtered and filtrate was concentrated under reduced pressure. The resulting product was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (3:7) to yield compound 31 as white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.23-7.42 (m, 4H), 3.79-3.87 (m, 2H), 3.34-3.48 (m, 1H), 3.13-3.25 (m, 1H), 2.58-2.75 (m, 1H), 1.58-1.80 (m, 2H), 1.46 (s, 9H), 1.24-1.39 (m, 1H), 0.93 (t, J=5.7 Hz, 6H).

(369) Compounds 32 and 34 were prepared from the corresponding carboxylic acid derivative in a similar manner to the procedure described for compound 31. Their characteristics are described in Table 4.

(370) TABLE-US-00005 TABLE 4 Cmpd. IUPAC name No. Structure .sup.1H NMR δ (ppm) 32 tert-Butyl 2-(2-((3-(4- White solid; .sup.1H NMR (CD.sub.3OD, bromophenyl)ureido)methyl)-N,4- 300 MHz) δ: 7.24-7.42 (m, 4H), dimethylpentanamido)acetate 3.90-4.21 (m, 2H), 3.32-3.41 (m, 02 1H), 3.22-3.27 (m, 1H), 3.17 (s, 3H), 1.51-1.71 (m, 2H), 1.46 (s, 9H), 1.20-1.37 (m, 2H), 0.91- 1.00 (m, 6H). 34 2-((3-(4- White solid; .sup.1H NMR (CD.sub.3OD, bromophenyl)ureido)methyl)- 300 MHz) δ: 7.23-7.42 (m, 4H), N,N,4-trimethylpentanamide 3.32-3.38 (m, 1H), 3.20-3.26 (m, 03 1H), 3.13 (s, 3H), 2.96 (s, 3H), 1.47-1.66 (m, 2H), 1.23-1.36 (m, 1H), 0.92 (dd, J = 6.3, 3.1 Hz, 6H).

Compound 33

N-((1H-tetrazol-5-yl)methyl)-2-((3-(4-bromophenyl)ureido)methyl)-4-methylpentanamide

(371) ##STR00104##

(372) To a solution of 2-[({[(4-Bromophenyl)amino]carbonyl}amino)methyl]-4-methylpentanoic acid (compound 7; 80 mg, 0.23 mmol) and 2 mL of anhydrous DMF at 25° C. was added DCC (48 mg, 0.23 mmol), and (1H-tetrazol-5-ylmethyl)amine hydrochloride (25 mg, 0.25 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was filtered and filtrate was concentrated under reduced pressure.

(373) ##STR00105##

(374) The resulting product was purified by medium pressure liquid chromatography on silica gel using methanol:dichloromethane (15:85) to yield compound 33 as white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.25-7.41 (m, 4H), 4.78-4.87 (m, 8H), 4.51 (d, J=15.8 Hz, 1H), 3.48 (dd, J=13.3, 4.5 Hz, 1H), 3.18 (dd, J=13.6, 9.2 Hz, 1H), 2.63 (br. s., 1H), 1.50-1.69 (m, 2H), 1.18-1.31 (m, 1H), 0.92 (dd, J=6.2, 3.8 Hz, 6H).

Compound 35. 2-((3-(4-bromophenyl)ureido)methyl)-4-methylpentanamide

(375) ##STR00106##

(376) To a solution of compound 7 (100 mg, 0.29 mmol) and 5 mL of anhydrous tetrahydrofuran under argon at −78° C. was added triethylamine (39 mg, 0.38 mmol), and ethyl chloroformate (38 mg, 0.37 mmol). The mixture was stirred at −78° C. for 30 minutes, then ammonia gas was bubbled into reaction flask for 1 minutes. The resulting mixture was stirred at 25° C. for 1 hour.

(377) ##STR00107##

(378) The mixture was quenched with water (1 mL) then extracted with ethyl acetate (20 mL). The layers were separated, and the organic layer was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The resulting product was purified by preparative thin layer chromatography on silica gel using an eluent of 100% ethyl acetate to yield compound 35 as a white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.26-7.42 (m, 4H), 3.32-3.40 (m, 1H), 3.14-3.27 (m, 1H), 2.59-2.75 (m, 1H), 1.47-1.69 (m, 2H), 1.17-1.30 (m, 1H), 0.94 (dd, J=6.4, 1.8 Hz, 6H).

Compound 36. ({2-[({[(4-bromophenyl)amino]carbonyl}amino)methyl]-4-methylpentanoyl} amino)acetic acid

(379) ##STR00108##

(380) A solution of compound 31 (181 mg, 0.40 mmol) and 8 mL of formic acid was stirred at 25° C. for 12 hours. The resulting reaction was quenched with water (10 mL), and the product was extracted with EtOAc. The organic layer was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The residue was rinsed four times with acetone:hexane (2:98) to yield compound 36 as a white solid. .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.22-7.42 (m, 4H), 3.81-4.04 (m, 2H), 3.37-3.53 (m, 1H), 3.10-3.24 (m, 1H), 2.54-2.76 (m, 1H), 1.77-1.91 (m, 2H), 1.14-1.32 (m, 1H), 0.93 (t, J=5.7 Hz, 6H).

Compound 37

2-(2-((3-(4-bromophenyl)ureido)methyl)-N,4-dimethylpentanamido)acetic acid

(381) ##STR00109##

(382) Compound 37 was prepared from the corresponding ester derivative in a similar manner to the procedure described for compound 36. It was obtained as a white solid; .sup.1H NMR (CD.sub.3OD, 300 MHz) δ: 7.25-7.41 (m, 4H), 4.03-4.23 (m, 2H), 3.33-3.46 (m, 1H), 3.25-3.29 (m, 1H), 3.17 (s, 3H), 1.49-1.73 (m, 2H), 1.22-1.37 (m, 2H), 0.90-1.05 (m, 6H).

Example 6—Synthesis of Compounds 38 and 39

(383) Compounds 38 and 39 were prepared as generally outlined in Scheme 1b.

Compound 38. Methyl 2-((2-(3-(4-bromophenyl)ureido)acetamidomethyl-4-methylpentanoate

(384) ##STR00110##

(385) To a solution of methyl 2-((2-aminoacetamido)methyl)-4-methylpentanoate (intermediate 2; 81 mg, 0.38 mmol) and 12 mL of methylene chloride at 25° C. was added 4-bromo-phenyl isocyanate (74 mg, 0.38 mmol) and triethylamine (0.08 mL, 0.57 mmol). The resulting mixture was stirred at 25° C. for 12 hours. The mixture was concentrated and the residue was purified by medium pressure liquid chromatography on silica gel using ethyl acetate:hexane (9:1) to yield compound 38 as white solid. .sup.1H NMR (CD.sub.3OD, 600 MHz) δ: 7.35 (s, 2H), 7.30-7.33 (m, 2H), 3.77-3.85 (m, 2H), 3.65 (s, 3H), 3.34-3.37 (m, 2H), 2.70-2.76 (m, 1H), 1.50-1.59 (m, 2H), 1.26-1.31 (m, 1H), 0.89 (dd, J=6.5, 1.8 Hz, 6H).

Compound 39. 2-((2-(3-(4-Bromophenyl)ureido)acetamido)methyl)-4-methylpentanoic acid

(386) ##STR00111##

(387) Compound 39 was prepared from compound 38 using similar conditions to those described for compound 7. Compound 39 was obtained as a white solid, .sup.1H NMR (CD.sub.3OD, 600 MHz) δ: 7.55-7.58 (m, 2H), 7.51-7.54 (m, 2H), 4.00-4.07 (m, 2H), 3.56-3.61 (m, 1H), 3.47 (m, 1H), 2.75 (br. s., 1H), 1.85 (dt, J=13.1, 6.7 Hz, 1H), 1.72-1.77 (m, 1H), 1.42 (dt, J=13.5, 6.7 Hz, 1H), 1.11 (t, J=6.7 Hz, 6H).

Biological Data

(388) Biological activity of some specific compounds of the invention is set forth in Table 5 and Table 6 below. CHO-Gα16 cells stably expressing FPR1 or FPR2 were cultured in: Ham's F12 nutrient media, 10% fetal bovine serum, 1% PSA (penicillin, streptomycin, amphotericin B antiobiotic/antimycotic), 400 μg/ml geneticin and 50 μg/ml hygromycin. In general, the day before the experiment, 18,000 cells/well were plated in a 384-well clear bottom poly-D-lysine coated plate. The following day the screening compound-induced calcium activity was assayed on the FLIPR.sup.Tetra. The drug plates were prepared in 384-well microplates using the EP3 and the MultiPROBE robotic liquid handling systems. Compounds were tested at concentrations ranging from 0.61 to 10,000 nM. Results are expressed as EC.sub.50 (nM) and efficacy values.

(389) TABLE-US-00006 TABLE 5 FPR2 FPR1 Ga16- Ga16- CHO CHO Ratio Compound EC.sub.50 EC.sub.50 FPR2:FPR1 Number Structure (% eff) (% eff) (EC.sub.50) 1 678 nM (0.47) 4030 nM (0.72) 0.17 2 2204 nM (0.78) 10449 nM (0.57) 0.21 3 1322 nM (0.95) >10K nM (0.50) <1 4 1527 nM (0.98) >19K nM (0.21) <1 5 541 nM (0.42) >73K nM (0.65) <1 6 >1K (0.67) >15K nM (0.39) ND 7 1297 nM (0.90) 35 nM (0.97) 37 8 1350 nM (0.92) 54 nM (1.05) 25 9 0 3004 nM (81) 163 nM (0.95) 18 10 1911 nM (0.94) 113 nM (0.98) 17 11 >1K (0.56) 1216 nM (0.92) Not determined 12 8085 nM (0.40) 1176 nM (0.81) 6.9 13 2669 nM (0.83) 2188 nM (0.97) 1.2 14 1324 nM (0.83) 243 nM (0.99) 5.4 15 351 nM (0.93) 67 nM (0.94) 5.2 16 3073 nM (0.62) 2846 nM (0.84) 1.1 17 2271 nM (0.71) 2150 nM (0.85) 1.1 18 246 nM (0.98) 47 nM (1.01) 5.2 19 0 48 nM (1.02) 14 nM (0.97) 3.4 20 82 nM (0.97) 51 nM (95) 1.6 21 1256 nM (0.89) 7 nM (0.99) 179 34 314 nM (0.92) 6320 nM (0.69) <1 35 975 nM (0.95) 7092 nM (0.80) 0.14

(390) TABLE-US-00007 TABLE 6 FPR2 FPR1 Ga16- Ga16- CHO CHO Ratio Compound EC.sub.50 EC.sub.50 FPR2:FPR1 Number Structure (% eff) (% eff) (EC.sub.50) 31 1500 nM (0.18) 552 nM (0.98) 2.7 32 1031 nM (0.89) 2514 nM (0.73) 0.41 33 130 nM (0.98) 13 nM (0.95) 10 36 1000 nM (0.43) 156 nM (0.95) 6.4 37 12 nM (1.04) 55 nM (0.96) 0.22 38 0 2173 nM (0.80) 2600 nM (0.77) 0.83 39 1680 nM (0.77) 19 nM (0.96) 88